EurekaMag.com logo
+ Site Statistics
References:
53,214,146
Abstracts:
29,074,682
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on Google+Follow on Google+
Follow on LinkedInFollow on LinkedIn

+ Translate

Disposition of enflurane in obese patients


Journal of Pharmacology and Experimental Therapeutics 215(2): 292-296
Disposition of enflurane in obese patients
The disposition of enflurane, a volatile halogenated anesthetic, was studied in obese (n = 26) and nonobese (n = 8) consenting adult subjects undergoing elective intra-abdominal surgical procedures. Enflurane and fluoride ion, a nephrotoxic metabolite of enflurane, were measured in the blood of subjects before, during and up to 24 hr after exposure to pharmacologically equivalent doses of enflurane [approximately 2.0 MAC hr (the minimal alveolar concentration at which 50% of humans do not respond to a painful stimulus)] Arterial enflurane in obese subjects reached maximal concentrations 3 times faster than nonobese subjects who reached similar blood levels 80 min after the initiation of anesthesia. The blood/gas partition coefficient for enflurane in the obese was found to be 30% lower than that in the nonobese (0.99 +/- 0.02 vs. 1.42 +/- 0.02) and may possibly explain the observed differences in enflurane uptake. The rate at which inorganic fluoride appeared in obese serum (5.5 microM/hr) was twice that seen in the nonobese group. No differences in urinary fluoride excretion were demonstrated. Maximum serum fluoride concentration occurred 2 hr postenflurane anesthesia in both groups with the obese having a 60% higher concentration (27.8 +/- 2.0 vs. 17.0 +/- 3.0 microM), indicating increased biotransformation in the obese. Hepatic triglyceride content was demonstrated to be unrelated to the increased enflurane biotransformation observed in obese subjects. Equations are presented for the estimation of mean maximum serum inorganic fluoride levels in both obese and nonobese subjects after enflurane anesthesia.

(PDF same-day service: $19.90)

Accession: 005170826

PMID: 7441496

DOI: 10.1097/00132586-198110000-00035



Related references

Factors influencing enflurane disposition in the obese. Anesthesia & Analgesia 59(7): 562, 1980

Plasma fluoride concentration and urinary fluoride excretion in obese and non-obese patients following enflurane anesthesia. Journal of Anesthesia 1(2): 148-154, 1987

Serum inorganic fluoride levels in obese patients during and after enflurane anesthesia. Anesthesia and Analgesia 58(5): 409-412, 1979

Metabolism and renal function in non obese and obese rats exposed to enflurane or isoflurane. Anesthesiology (Hagerstown) 61(3 PART A): A264, 1984

Serum fluoride levels in morbidly obese patients: enflurane compared with isoflurane anaesthesia. Anaesthesia 42(7): 685-689, 1987

Theophylline disposition in obese pediatric patients. Pharmacotherapy 9(3): 195, 1989

Verapamil pharmacodynamics and disposition in obese hypertensive patients. Journal of Cardiovascular Pharmacology 11(2): 209-215, 1988

Thiopental disposition in lean and obese patients undergoing surgery. Anesthesiology 56(4): 269-274, 1982

Cefotiam disposition in markedly obese athlete patients, Japanese sumo wrestlers. Antimicrobial Agents and ChemoTherapy 33(8): 1188-1192, 1989

Effects of basal insulin supplementation on disposition of mixed meal in obese patients with NIDDM. Diabetes 38(3): 291-303, 1989